ArticleBMJ (Clinical research ed.)2023
Use of health technology assessment in drug reimbursement decisions in China.
Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Deriving Health Utility Values Using Mapping Methods Among the Chinese Population: A Systematic Review.Applied health economics and health policy · 2026Pooled it
- Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016-2024.BMJ open · 2024Pooled it
- What Drives Public Preference for Rare Drugs Coverage in China? Insights From a Multi-Center Discrete Choice Experiment.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Prediction Error in Quality-Adjusted Life Years in Economic Evaluations of Immune Checkpoint Inhibitors: A Comparison Based on Projected and Observed Updated Survival.PharmacoEconomics - open · 2026Article
- Cost-utility of once-weekly insulin icodec versus once-daily basal insulins for type 2 diabetes in China.Diabetes, obesity & metabolism · 2026Article
- Construction of a comprehensive value assessment framework for renal denervation therapy: a decision-support tool for Chinese hospital management.Frontiers in public health · 2026Article
- Patient Priorities for Coverage of New Antihypertensive Drugs: A Discrete Choice Experiment in China.Patient preference and adherence · 2026Article
- Mapping Dermatology Life Quality Index with EQ-5D health utility index score in Chinese patients with moderate to severe psoriasis.Journal of comparative effectiveness research · 2025Article
- Observational
- Global research on patient involvement in health technology assessment: a bibliometric analysis.Global health research and policy · 2025Article
- How was published evidence used in model-based cost - utility analysis for lung cancer?Health economics review · 2025Article
- Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China.Frontiers in public health · 2025Article
- Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.Applied health economics and health policy · 2024Review
- Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.The Lancet regional health. Western Pacific · 2024Article
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.BMJ global health · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.